Investors Urged to Join Immutep Limited Securities Fraud Class Action with Schall Law Firm
Class Action Alert: Immutep Limited Securities Fraud Lawsuit
The Schall Law Firm, a nationally recognized firm specializing in shareholder rights litigation, is reminding investors of a significant class action lawsuit against Immutep Limited. This action concerns alleged violations of the Securities Exchange Act by the company, specifically under sections §§10(b) and 20(a), along with Rule 10b-5 set forth by the U.S. Securities and Exchange Commission (SEC).
Key Details of the Case
Investors who purchased securities in Immutep during the time frame of March 24, 2025, to March 12, 2026 (inclusive), are strongly encouraged to reach out to the Schall Law Firm before the July 6, 2026 deadline. This lawsuit arises from allegations that Immutep made misleading statements and omissions that impacted shareholders' rights and investments.
According to the firm, the Complaint indicates that Immutep concealed the negative results of its TACTI-004 trial for the drug eftilagimod alfa (often referred to as efti). Although the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was demonstrating
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.